

## **Quality Transformation Initiative (QTI) Memo**

November 2024

The purpose of this memo aims to:

1. Announce the extension of the QTI CIS10 Allowance Program to MY2024 and MY2025
2. Clarify QTI COL measure reporting for MY2024 and MY2025

### **Extension of QTI Childhood Immunization Status Combo 10 (CIS10) Allowance Program**

Covered California introduced a novel program in 2023 that allow Issuers to submit supplemental data for any measure denominator-eligible child who completed the full CIS10 vaccination series but received their second flu shot after their birthday. To qualify for this allowance, the second influenza vaccine must be administered within 90 days after the child's second birthday.

In the early assessment of the program's first year of implementation for QTI MY2023, a total of four Issuers have participated. Among them, 14 children were approved for the allowance, resulting in an estimated savings of approximately ~\$852,535 in QTI payments for MY2023.

We are excited to announce that we are extending this program to the remaining contract years for QTI assessment, MY2024 and MY2025. The submission process will remain the same as previously outlined, and more information regarding submission dates will be shared in Spring 2025 via Carrier Call.

### **Clarification on QTI Colorectal Cancer Screening (COL) Measure Reporting for MY2024 and MY2025**

Following the Carrier Call on July 31, 2024, this communication provides clarification regarding the approach to QTI COL measure reporting for MY2024 and MY2025, with a focus on age cohorts and reporting requirements.

For MY2024 and MY2025, Covered California will utilize the retired Colorectal Cancer Screening rate as specified in MY2023 for QRS<sup>1,2</sup> specifications, which encompass the full age range of 45-75 years. Issuers will generate, or have their vendor generate, a separate sample and hybrid rates based on the retired Colorectal Cancer Screening rate as specified in MY2023 for QRS specifications. Covered California will then extract the relevant age cohort data for the 51-75 age group for QTI assessments.

Additionally, Covered California will not require QHP issuers to have the Colorectal Cancer Screening rate hybrid measure for MY2024 and MY2025 QTI assessment reported through patient-level data (PLD) file to be audited by the QHP's NCQA vendor.

This approach is designed to streamline processes and reduce operational burden, enabling QHPs/vendors to continue using the retired Colorectal Cancer Screening rate as specified in MY2023 for QRS specifications without requiring modifications.

**Sources:**

[<sup>1</sup>MY 2023 HEDIS® for QRS](#) (2024 Quality Rating System Measure Technical Specifications)

[<sup>2</sup>Measurement Year \(MY\) 2023 HEDIS® for the Quality Rating System \(QRS\): Technical Update](#)

<https://www.ncqa.org/wp-content/uploads/QRS-HEDIS®-MY-2024-Technical-Update-Memo.pdf>